Skip to main content

HACIA EL DESARROLLO DE NUEVAS TERAPIAS EN ANEMIA DE FANCONI

SAF2009-07164

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2009
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre CENTRO DE INVESTIGACION ENERGETICA MEDIOAMBIENTAL Y TECNOLOGICA (CIEMAT)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeted gene therapy and cell reprogramming in Fanconi anemia

  • Río, Paula
  • Baños, Rocío
  • Lombardo, Angelo
  • Quintana-Bustamante, Oscar|||0000-0002-6869-7006
  • Alvarez, Lara
  • Garate, Zita
  • Genovese, Pietro
  • Almarza, Elena
  • Valeri, Antonio
  • Díez, Begoña
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Torres, Yaima
  • Trujillo, Juan P.
  • Murillas, Rodolfo
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Samper, Enrique
  • Surralles, Jordi|||0000-0002-4041-7519
  • Gregory, Philip D.
  • Holmes, Michael C.
  • Naldini, Luigi
  • Bueren, Juan|||0000-0002-3228-7013
Gene targeting is progressively becoming a realistic therapeutic alternative in clinics. It is unknown, however, whether this technology will be suitable for the treatment of DNA repair deficiency syndromes such as Fanconi anemia (FA), with defects in homology-directed DNA repair. In this study, we used zinc finger nucleases and integrase-defective lentiviral vectors to demonstrate for the first time that FANCA can be efficiently and specifically targeted into the AAVS1 safe harbor locus in fibroblasts from FA-A patients. Strikingly, up to 40% of FA fibroblasts showed gene targeting 42 days after gene editing. Given the low number of hematopoietic precursors in the bone marrow of FA patients, gene-edited FA fibroblasts were then reprogrammed and re-differentiated toward the hematopoietic lineage. Analyses of gene-edited FA-iPSCs confirmed the specific integration of FANCA in the AAVS1 locus in all tested clones. Moreover, the hematopoietic differentiation of these iPSCs efficiently generated disease-free hematopoietic progenitors. Taken together, our results demonstrate for the first time the feasibility of correcting the phenotype of a DNA repair deficiency syndrome using gene-targeting and cell reprogramming strategies.